The statement confirms that the FDA has given NWBO no feedback that the P3 trial will be approvable. It is truly a risk factor that shareholders should understand.
The company did not make the statements under penalty of perjury in an SEC filings.
EMA and US clinicaltrial.gov are both posting sites for list clinical trial protocols -- all sponsors are now obligated to post their protocols on the sites. That is NOT an approval
From the site: "ClinicalTrials.gov: Relies on sponsors or investigators to submit and update information about studies."
Market Data 
Markets 
AI
